ArticleESMO open2020

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials.

Yutaka Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.